Literature DB >> 2274575

Resistance to alkylating agents and cisplatin: insights from ovarian carcinoma model systems.

R P Perez1, T C Hamilton, R F Ozols.   

Abstract

The curative potential of chemotherapy for ovarian cancer is frequently not realized due to platinum and alkylating agent resistance. Mechanisms which may contribute to the resistant phenotype include alterations in drug transport, increased levels of sulfhydryl molecules (and/or related enzymes), and enhanced DNA repair. We have developed several ovarian cancer cell lines resistant to platinum compounds and alkylating agents. Increased levels of glutathione and enhanced DNA repair are major determinants of chemoresistance in these cells. Modulation of these processes with buthionine sulfoximine (BSO), aphidicolin, arc-C, etc. partially reverses in vitro resistance. Similar clinical treatment strategies are under investigation.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2274575     DOI： 10.1016/0163-7258(90)90015-t

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN： 0163-7258            Impact factor:   12.310


  13 in total

1.  Cisplatin but not BCNU inhibits urokinase-type plasminogen activator levels in human glioblastoma cell lines in vitro.

Authors:  Y Go; S K Chintala; A Rayford; E Gagercas; F Ali-Osman; B Venkaiah; R Sawaya; Z Gokaslan; G L Nicolson; J S Rao
Journal:  Clin Exp Metastasis       Date:  1997-07       Impact factor: 5.150

2.  Dinuclear platinum anticancer complexes with fluorescent N,N'-bis(aminoalkyl)-1,4-diaminoanthraquinones: cellular processing in two cisplatin-resistant cell lines reflects the differences in their resistance profiles.

Authors:  Ganna V Kalayda; Bart A J Jansen; Peter Wielaard; Hans J Tanke; Jan Reedijk
Journal:  J Biol Inorg Chem       Date:  2005-04-12       Impact factor: 3.358

3.  Specificity and prognostic validation of a polyclonal antibody to detect Six1 homeoprotein in ovarian cancer.

Authors:  Lubna Qamar; Erin Deitsch; Aaron N Patrick; Miriam D Post; Monique A Spillman; Ritsuko Iwanaga; Andrew Thorburn; Heide L Ford; Kian Behbakht
Journal:  Gynecol Oncol       Date:  2012-02-12       Impact factor: 5.482

4.  High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis.

Authors:  A K Godwin; A Meister; P J O'Dwyer; C S Huang; T C Hamilton; M E Anderson
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-01       Impact factor: 11.205

Review 5.  WR2721 as a modulator of cisplatin- and carboplatin-induced side effects in comparison with other chemoprotective agents: a molecular approach.

Authors:  M Treskes; W J van der Vijgh
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

6.  Cytotoxicity of antitumor platinum complexes with L-buthionine-(R,S)-sulfoximine and/or etanidazole in human carcinoma cell lines sensitive and resistant to cisplatin.

Authors:  S E Brooks; T T Korbut; N P Dupuis; S A Holden; B A Teicher
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

7.  Intracellular glutathione and cytotoxicity of platinum complexes.

Authors:  L Pendyala; P J Creaven; R Perez; J R Zdanowicz; D Raghavan
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

Review 8.  Cellular accumulation of the anticancer agent cisplatin: a review.

Authors:  D P Gately; S B Howell
Journal:  Br J Cancer       Date:  1993-06       Impact factor: 7.640

9.  Modulation of cisplatin cytotoxicity by sulphasalazine.

Authors:  S Awasthi; R Sharma; S S Singhal; N K Herzog; M Chaubey; Y C Awasthi
Journal:  Br J Cancer       Date:  1994-08       Impact factor: 7.640

10.  Combination therapy with cisplatin and nifedipine induces apoptosis in cisplatin-sensitive and cisplatin-resistant human glioblastoma cells.

Authors:  S Kondo; D Yin; T Morimura; H Kubo; S Nakatsu; J Takeuchi
Journal:  Br J Cancer       Date:  1995-02       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.